Le Lézard
Classified in: Health
Subject: TRI

Gencove announces Phase I SBIR grant to validate polygenic risk score estimation from low-pass sequencing


NEW YORK, April 25, 2019 /PRNewswire/ -- Gencove, the leading low-pass sequencing platform announced today the receipt of a Phase I grant from the National Human Genome Research Institute under the auspices of the Small Business Innovation Research (SBIR) program of the National Institutes of Health. The grant will be used to validate methods for accurate calculation of polygenic risk scores from low-pass sequencing data that allow for population-scale screening applications, with a first application to coronary artery disease.

As clinical evidence for the benefit of screening patients for polygenic risk of diseases continues to accumulate, there will be increasing need for a scalable and flexible assay to measure these scores. Gencove's low-pass genome sequencing combined with its imputation algorithms can address the technological challenge to provide a highly accurate estimate of a polygenic risk score across ethnic groups using an assay that can scale financially and operationally to entire health care systems. Low-pass sequencing is an approach to combine the throughput and cost-effectiveness of genotyping arrays with the accuracy and population portability of whole genome sequencing.

Regarding this award, Gencove's CEO Joe Pickrell said, "The flexibility, operational efficiency, cost-effectiveness, and population-agnostic nature of low-pass sequencing make it a great choice for calculating polygenic risk scores at scale."

Gencove has recently raised a $3.2 million investment led by Spero Ventures.

About Gencove

Gencove is a spin-out of the New York Genome Center dedicated to making genomic data more accessible and interpretable through the development of molecular and computational tools. Gencove's flagship product is its low-pass genome sequencing platform; the company operates a laboratory in New York and offers both low-pass sequencing and analytics software as a service, with customers that include top academic institutions, biotechnology and pharmaceutical companies. More information is available at www.gencove.com.

Contact: Maria Vazquez, maria.vazquez@gencove.com

SOURCE Gencove


These press releases may also interest you

at 22:30
Seattle Genetics, Inc. today announced the pricing of an underwritten public offering of 7,142,858 shares of its common stock at a price to the public of $70.00 per share. All of the shares are being sold by Seattle Genetics. The gross proceeds to...

at 21:33
Healthcare providers are focused on delivering care. That means always seeking better ways to improve patient outcomes, make reporting easier, and meet financial goals. It's a big job that never ends. That's why  Prista Corporation Chief Mission...

at 21:18
Global Vitamin D Testing Market: About this market Vitamin D is needed to maintain serum calcium and phosphate concentration to regularize the mineralization of bone and tooth. This vitamin D testing market analysis considers sales from both...

at 21:07
Digital Therapeutics and Their Impact on HealthcareSummaryRead the full report: https://www.reportlinker.com/p05795614/?utm_source=PRN Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx)...

at 21:00
Is there some way to bring a software as a medical device (SaMD) product to market faster? The answer is yes, with the Software Precertification Program. The pre-cert pathway regulatory model expedites pre-market approval while assessing the safety...

at 20:50
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2019 on Thursday, August 1, 2019, following the close of the market. The company will discuss...



News published on 25 april 2019 at 21:17 and distributed by: